Skip to content

Biomarin Pharmaceutical Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 2, 2026 results vs estimates

Biomarin Pharmaceutical Inc · E.BMRN.NASDAQ · United States
Use symbol E.BMRN.NASDAQ in our API & Excel add-in to retrieve this data ↓
55.35
(-0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -50%
Trend -50%
Bubble Risk LOW
Realised Volatility (20D) 27.49%

Biomarin Pharmaceutical Inc Forecast

Biomarin Pharmaceutical Inc short-term momentum is negative (up over 1 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is negative (2 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 27.5% a year, a typical one-standard-deviation range is 53.21–57.49 over a week, 50.96–59.74 over a month and 40.13–70.57 over a year. (Signals as of 1 Nov 2026.)

Biomarin Pharmaceutical Inc Price Chart

MacroFinance.ai

Biomarin Pharmaceutical Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Biomarin Pharmaceutical Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Biomarin Pharmaceutical Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Biomarin Pharmaceutical Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Biomarin Pharmaceutical Inc
P/S
2.93x
Cheap vs own history
QoQ −22.9%
YoY −13.6%
now 2.93162.93 low3.98 high
ⓘP/S As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Biomarin Pharmaceutical Inc
P/B
1.71x
Cheap vs own history
QoQ −16.4%
YoY −1.2%
now 1.71281.65 low2.07 high
ⓘP/B As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Biomarin Pharmaceutical Inc
EV/EBITDA
31.82x
Mid-range vs own history
QoQ −24.6%
YoY +155.3%
now 31.821612.12 low42.54 high
ⓘEV/EBITDA As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Biomarin Pharmaceutical Inc
EV/Sales
3.88x
Mid-range vs own history
QoQ −18.9%
YoY +24.6%
now 3.87662.92 low4.82 high
ⓘEV/Sales As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Biomarin Pharmaceutical Inc
FCF Yield
5.2%
Mid-range vs own history
QoQ −8.0%
YoY −33.8%
now 5.20634.77 low8.07 high
ⓘFCF Yield As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Biomarin Pharmaceutical Inc
Earnings Yield
-0.2%
Weak vs own history
QoQ −131.7%
YoY −103.6%
now -0.1784-0.18 low5.08 high
ⓘEarnings Yield As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Biomarin Pharmaceutical Inc
Market Cap
$10.7B
Lowest in 5 years
QoQ −17.3%
YoY +2.0%
now 10715.206510,237 low13,078 high
ⓘMarket Cap As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Biomarin Pharmaceutical Inc
Net Debt
$3.5B
High vs own history
QoQ +3.8%
YoY −495.4%
now 3454.203-917.74 low3,454 high
ⓘNet Debt As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Biomarin Pharmaceutical Inc
Net Debt / EBITDA
7.76x
High vs own history
QoQ −10.1%
YoY −785.9%
now 7.7574-1.62 low8.63 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Biomarin Pharmaceutical Inc
Current Ratio
2.44x
Weak vs own history
QoQ +2.4%
YoY −49.4%
now 2.4432.39 low5.81 high
ⓘCurrent Ratio As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Biomarin Pharmaceutical Inc
Quick Ratio
1.32x
Weak vs own history
QoQ +0.6%
YoY −57.2%
now 1.32391.32 low4.2 high
ⓘQuick Ratio As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Biomarin Pharmaceutical Inc
Interest Coverage
1.32x
Weak vs own history
QoQ −52.6%
YoY −98.0%
now 1.31951.32 low64.46 high
ⓘInterest Coverage As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Biomarin Pharmaceutical Inc
Debt / Equity
0.67x
High vs own history
QoQ +0.8%
YoY +571.4%
now 0.66980.1 low0.67 high
ⓘDebt / Equity As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Biomarin Pharmaceutical Inc
Piotroski F-Score
2
Weak vs own history
QoQ −50.0%
YoY −77.8%
now 22 low9 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Biomarin Pharmaceutical Inc
Altman Z-Score
1.84
Weak vs own history
QoQ −11.0%
YoY −65.1%
now 1.83961.81 low6.02 high
ⓘAltman Z-Score As of 22 Nov 2026.See Biomarin Pharmaceutical Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Biomarin Pharmaceutical Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Biomarin Pharmaceutical Inc fundamentals: income statement, balance sheet & cash flow

Biomarin Pharmaceutical Inc reported revenue of $3.22bn and net income of $348.9m in FY2025, the year ended 31 December 2025 — revenue up 12.9% and net income down 18.3% on the prior year. Free cash flow was $725.0m. These figures are as reported in the filings, not restated: 28 fiscal years and 111 quarters of history, back to December 1998. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$3.22bn
+12.9%
Net income
$348.9m
-18.3%
Gross margin
77.13%
Free cash flow
$725.0m
+52.5%
Net debt
-$668.8m
Shares short (30 Oct 2026)
14.12m
5.77 days to cover
Biomarin Pharmaceutical Inc income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue3,221.32,853.92,419.22,096.01,846.3
Cost of revenue736.8580.2532.1503.0470.5
Gross profit2,484.42,273.71,887.21,593.01,375.8
Research & development921.9747.2746.8649.6628.8
Selling, general & admin.——954.6782.4829.3
Operating income533.5484.2185.8161.0-82.3
EBITDA572.9650.5306.8265.447.4
Interest expense10.912.717.316.015.3
Pre-tax income482.5541.8188.6149.6-75.4
Income tax133.6114.920.98.0-11.3
Net income348.9426.9167.6141.6-64.1

Download Biomarin Pharmaceutical Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BMRN.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 28 fiscal years and 111 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Biomarin Pharmaceutical Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Biomarin Pharmaceutical Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Biomarin Pharmaceutical Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Biomarin Pharmaceutical Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Biomarin Pharmaceutical Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Biomarin Pharmaceutical Inc (United States)

Biomarin Pharmaceutical Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Biomarin Pharmaceutical Inc?
Biomarin Pharmaceutical Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Biomarin Pharmaceutical Inc price?
The latest close is 55.35 (1 Nov 2026), -0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Biomarin Pharmaceutical Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is negative (1 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is negative (2 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Biomarin Pharmaceutical Inc?
20-day realised volatility is 27.5% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 7.9% over a month and 3.9% over a week.
What factors affect Biomarin Pharmaceutical Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Biomarin Pharmaceutical Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Biomarin Pharmaceutical Inc?
58 backtested tactical asset allocation strategies trade Biomarin Pharmaceutical Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Biomarin Pharmaceutical Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Biomarin Pharmaceutical Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Biomarin Pharmaceutical Inc historical data?
In the Free historical data section of this page: the last 10 years of Biomarin Pharmaceutical Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Biomarin Pharmaceutical Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Biomarin Pharmaceutical Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BMRN.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2060.41
2026-11-1961.42
2026-11-1861.43
2026-11-1758.51
2026-11-1657.99
2026-11-1357.23
2026-11-1256.7
2026-11-1158.33
2026-11-1057.13
2026-11-0957.18
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.